scholarly journals Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer

2010 ◽  
Vol 13 (3) ◽  
pp. 149-154 ◽  
Author(s):  
Yuji Ueda ◽  
Hisakazu Yamagishi ◽  
Daisuke Ichikawa ◽  
Kazuma Okamoto ◽  
Eigo Otsuji ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Combination Chemotherapy ◽  
Phase Ii Study ◽  
Weekly Paclitaxel ◽  
Multicenter Phase

Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer

2007 ◽  
Vol 60 (6) ◽  
pp. 863-869 ◽  
Author(s):  
Jong Gwang Kim ◽  
Sang Kyun Sohn ◽  
Hong Suk Song ◽  
Ki-Young Kwon ◽  
Young Rok Do ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Combination Chemotherapy ◽  
Phase Ii Study ◽  
Weekly Paclitaxel ◽  
Multicenter Phase

Multicenter phase II study of triplet combination chemotherapy with paclitaxel, cisplatin, and S-1 for advanced gastric cancer (OGSG 0703).

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 124-124
Author(s):  
Kazumasa Fujitani ◽  
Yutaka Kimura ◽  
Hiroshi Imamura ◽  
Masahiro Gotoh ◽  
Shohei Iijima ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Combination Chemotherapy ◽  
Phase Ii Study ◽  
Performance Status ◽  
Locally Advanced ◽  
Progression Free Survival ◽  
Statistical Hypothesis ◽  
Multicenter Phase

124 Background: Docetaxel combined with cisplatin and 5-fluorouracil is active in advanced gastric cancer, but not generally accepted because of its substantial toxicities. We conducted a multicenter phase II study of triplet combination using paclitaxel, cisplatin and S-1 (PCS) as first-line treatment for advanced gastric cancer. Methods: Patients with previously untreated, locally advanced or metastatic measurable gastric cancer, a performance status < 2, age of 20-75 years, and adequate organ functions were given intravenous paclitaxel at 70 mg/m2 and cisplatin at 30 mg/m2 on days 1 and 15, plus oral S-1 at 40 mg/m2 b.i.d. on days 1 to 21, followed by 2-week rest, repeated every 5 weeks. Treatment was continued until disease progression or unacceptable toxicity occurred, or the patient refused the therapy. Study endpoints included overall response rate (ORR) as primary, progression free survival (PFS), overall survival (OS), and toxicity. Sample size of 40 patients was determined to reject the ORR of 55% under the expectation of 75% with a power of 80% and a one-sided α of 5%. Results: A total of 52 patients were enrolled in this study, among whom 49 were assessable for efficacy and 51 assessable for toxicity. ORR was 46.9% (95% CI: 32.5-61.7%). The median PFS and median OS were 5.4 months (95% CI: 4.1-7.0) and 11.5 months (95% CI: 7.3-16.1), respectively. Frequent grade 3/4 toxicities were neutropenia (51%), leucopenia (25%), anemia (20%), hyponatremia (16%), anorexia (14%), diarrhea (8%) and fatigue (8%). There was no treatment-related death. Conclusions: Triplet combination chemotherapy with PCS demonstrated superior feasibility with promising antitumor activity, though which did not meet the statistical hypothesis, for advanced gastric cancer.

Phase II study of weekly paclitaxel by one-hour infusion for advanced gastric cancer

Surgery Today ◽  
2008 ◽  
Vol 38 (11) ◽  
pp. 1013-1020 ◽  
Author(s):  
Yasunori Emi ◽  
Manabu Yamamoto ◽  
Ikuo Takahashi ◽  
Hiroyuki Orita ◽  
Yoshihiro Kakeji ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Weekly Paclitaxel

scholarly journals Multicenter Phase II Study of Combination Therapy with Oral S-1 Plus Cisplatin in Elderly Patients with Advanced Gastric Cancer

2014 ◽  
Vol 25 ◽  
pp. ii39
Author(s):  
Iwasa Satoru ◽  
Hamaguchi Tetsuya ◽  
Nagashima Kengo ◽  
Goto Masahiro ◽  
Okazaki Shunsuke ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Combination Therapy ◽  
Elderly Patients ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Multicenter Phase

scholarly journals A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604)

2020 ◽  
Vol 24 (1) ◽  
pp. 190-196
Author(s):  
Akihito Kawazoe ◽  
Daisuke Takahari ◽  
Chin Keisho ◽  
Yoshiaki Nakamura ◽  
Takashi Ikeno ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Multicenter Phase

Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer

2010 ◽  
Vol 67 (3) ◽  
pp. 527-532 ◽  
Author(s):  
Jin Young Kim ◽  
Young Rok Do ◽  
Keon Uk Park ◽  
Jong Gwang Kim ◽  
Yee Soo Chae ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Combination Chemotherapy ◽  
Phase Ii Trial ◽  
Multicenter Phase

scholarly journals A multicenter phase II study of TAS-114 in combination with S-1 in patients with pre-treated advanced gastric cancer (EPOC1604)

2019 ◽  
Vol 30 ◽  
pp. v303-v304
Author(s):  
D. Takahari ◽  
A. Kawazoe ◽  
Y. Nakamura ◽  
H. Tamura ◽  
M. Fukutani ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Multicenter Phase
Sign in / Sign up

Export Citation Format

Share Document